Catalent, Inc. (NASDAQ:CTLT) – KeyCorp issued their Q2 2018 earnings per share (EPS) estimates for shares of Catalent in a research note issued to investors on Wednesday, according to Zacks Investment Research. KeyCorp analyst M. Mishan forecasts that the company will post earnings per share of $0.29 for the quarter. KeyCorp also issued estimates for Catalent’s Q3 2018 earnings at $0.41 EPS, Q4 2018 earnings at $0.64 EPS, FY2018 earnings at $1.48 EPS and FY2019 earnings at $1.73 EPS.
Several other equities research analysts have also weighed in on the company. Zacks Investment Research lowered Catalent from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Bank of America Corporation reissued a “buy” rating and set a $40.00 target price (up previously from $38.00) on shares of Catalent in a research report on Tuesday, August 29th. William Blair reissued an “ourperform” rating on shares of Catalent in a research report on Tuesday, August 29th. Piper Jaffray Companies reissued a “buy” rating and set a $45.00 target price on shares of Catalent in a research report on Tuesday, August 29th. Finally, ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, September 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $42.11.
ILLEGAL ACTIVITY WARNING: “Catalent, Inc. (NASDAQ:CTLT) Forecasted to Earn Q2 2018 Earnings of $0.29 Per Share” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/12/equities-analysts-offer-predictions-for-catalent-incs-q2-2018-earnings-ctlt.html.
Shares of Catalent (CTLT) opened at $38.00 on Friday. Catalent has a 12-month low of $22.94 and a 12-month high of $43.39.
Catalent (NASDAQ:CTLT) last issued its earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.01. Catalent had a return on equity of 36.29% and a net margin of 10.02%. The business had revenue of $543.90 million for the quarter, compared to analyst estimates of $490.75 million. During the same quarter last year, the company earned $0.16 EPS. The business’s quarterly revenue was up 23.0% on a year-over-year basis.
Large investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC increased its holdings in shares of Catalent by 72.2% in the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares during the period. Quantbot Technologies LP increased its holdings in shares of Catalent by 110.7% in the second quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after purchasing an additional 1,804 shares during the period. Fortaleza Asset Management Inc. acquired a new position in shares of Catalent in the third quarter valued at approximately $164,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Catalent by 12.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after purchasing an additional 559 shares during the period. Finally, Advisor Group Inc. increased its holdings in shares of Catalent by 1.3% in the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares during the period.
In other news, SVP Christine Dolan sold 1,594 shares of the business’s stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $38.75, for a total value of $61,767.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Get a free copy of the Zacks research report on Catalent (CTLT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.